ONCOLYTICS director granted options on 30,000 shares

ONCOLYTICS BIOTECH INC director Bernd R. Seizinger received a grant of stock options covering 30,000 common shares.

Accepted by SEC EDGAR 06/03/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ONCOLYTICS BIOTECH INC director Bernd R. Seizinger received a grant of stock options covering 30,000 common shares. The options have an exercise price of $1.06 per share, matching the closing price on the Nasdaq Capital Market on June 1, 2026, and expire on June 1, 2036.

The award vests in three equal annual installments starting on June 1, 2027, contingent on his continued service or employment on each vesting date. Following this grant, he holds stock options on 30,000 shares directly.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Seizinger Bernd R.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 30,000 contracts (Direct)

Holdings Before and After: Stock Option, 0 to 30,000 contracts (Direct)

Footnotes (2)

1. F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
2. F2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Key Figures

Option grant size: 30,000 shares Exercise price: $1.06 per share Expiration date: June 1, 2036 +1 more

4 metrics

Option grant size 30,000 shares Stock options granted to director on June 1, 2026

Exercise price $1.06 per share Equal to Nasdaq closing price on June 1, 2026

Expiration date June 1, 2036 Stock option term end date

Vesting schedule 3 equal annual tranches First tranche vests June 1, 2027, subject to continued service

Key Terms

Stock Option, exercise price, vests in three equal annual installments, expiration date

4 terms

Stock Option financial

"security_title: "Stock Option" and underlying security: "Common Shares""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The exercise price is equal to the closing price of the Issuer's common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in three equal annual installments financial

"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027"

expiration date financial

"expiration_date: 2036-06-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ONCY director Bernd R. Seizinger report in this Form 4?

Bernd R. Seizinger reported receiving stock options for 30,000 ONCY common shares. These were granted as compensation, giving him the right to buy shares at a fixed price if vesting and exercise conditions are met in future years.

How many ONCY shares are covered by Seizinger’s new stock options?

The grant covers options on 30,000 ONCOLYTICS BIOTECH INC common shares. This represents potential future ownership if he chooses to exercise the options after they vest and before they expire in 2036.

What is the exercise price of Bernd R. Seizinger’s ONCY stock options?

The stock options have an exercise price of $1.06 per share. According to the disclosure, this equals the closing price of ONCY common stock on the Nasdaq Capital Market on the June 1, 2026 grant date.

When do Bernd R. Seizinger’s ONCY options vest and expire?

The options vest in three equal annual installments starting on June 1, 2027. They expire on June 1, 2036, giving a long window to satisfy vesting conditions and decide whether to exercise.

Is this ONCY Form 4 a market purchase or sale of shares?

No, the Form 4 reports a grant of stock options, not a market trade. It is a compensation-related acquisition, giving Seizinger the right to buy shares later rather than reflecting immediate buying or selling activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seizinger Bernd R.

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.06(1)	06/01/2026		A		30,000		(2)	06/01/2036	Common Shares	30,000	$0	30,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.

2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

	/s/ Kirk Look, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)